Author:
Lin Chang-Ting,Su Po-Jung,Huang Shih-Yu,Wu Chia-Che,Wang Hung-Jen,Cheng Yuan-Tso,Luo Hao-Lun,Chen Chien-Hsu,Liu Ting-Ting,Huang Chun-Chieh,Su Yu-Li
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Pharmacology,Immunology,Immunology and Allergy
Reference61 articles.
1. European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: summary of the 2020 guidelines;Witjes;Eur Urol,2020
2. EAU–ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—an International Collaborative Multi-Stakeholder Effort: under the auspices of the EAU and ESMO Guidelines Committees;Horwich;Ann Oncol,2019
3. Systemic therapy for advanced urothelial carcinoma: current standards and treatment considerations;Dietrich;Am Soc Clin Oncol Educ Book,2018
4. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000
5. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献